Visceral but Not Subcutaneous Adipose Tissue

Abstract 15886: Visceral but Not Subcutaneous Adipose Tissue Associa…laque Beyond Cardiovascular Risk Factors in Psoriasis | Circulation

SCIENCE VOLUNTEER

WARNING SIGNS

Search

11/12/17, 9(06 PM

Advanced Search

DONATE

Hello, Guest!

Circulation HOME

ABOUT THIS JOURNAL

RESOURCES

ALL ISSUES

MY ALERTS

SUBJECTS

SIGN IN

JOIN

BROWSE FEATURES

AHA JOURNALS

Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Failure to honor embargo policies (http://newsroom.heart.org/newsmedia/embargo-policy) will result in the abstract being withdrawn and barred from presentation. CARDIOMETABOLIC HEALTH AND DIABETES SESSION TITLE: BODY FAT, BMI, AND CV RISK

Abstract 15886: Visceral but Not Subcutaneous Adipose Tissue Associates With High Risk Coronary Plaque Beyond Cardiovascular Risk Factors in Psoriasis Joshua P Rivers, Aparna Sajja, Jonathan H Chung, Amit K Dey, Joseph B Lerman, Anshuma Rana, Aditya Goyal, Agastya D Belur, Aditya A Joshi, Justin A Rodante, Martin P Playford, Jianhua Yao, Veit Sandfort, David A Bluemke, Joel M Gelfand, Marcus Y Chen, Nehal N Mehta

Circulation. 2017;136:A15886

Article

Info & Metrics

Abstract http://circ.ahajournals.org/content/136/Suppl_1/A15886

This Issue Circulation November 1, 2017, Page 1 of 5


Introduction: Psoriasis (PSO), a chronic inflammatory disease associated with an accelerated risk of early MI and adipose tissue dysregulation, provides an ideal clinical model to study inflammatory atherogenesis. Recently, PSO patients were shown to have increased high-risk plaque (HRP) prevalence by CCTA when compared to healthy controls. However, the interrelationship between visceral adiposity and total HRP score in PSO patients has yet to be characterized. Hypothesis: We hypothesized that VAT volume would associate with total HRP score by CCTA in a PSO cohort. Methods: Consecutive PSO patients (n=105) underwent CT and CCTA (Toshiba 320 slice) scans to measure abdominal adiposity volume and characterize HRP morphology respectively. HRP phenotyping was performed using QAngio CT (Medis). HRP was defined as either positive remodeling (index > 1.1) or low attenuation (< 30 HU) and tallied into an HRP score. The relationship between VAT volume and HRP score was analyzed by multivariable linear regression (STATA 12) Results: Patients were middle-aged, mostly male, had moderate PSO severity, and low cardiovascular (CV) disease risk by Framingham risk score (Table 1). Multivariable regression analysis revealed a direct association of VAT with HRP total score beyond adjustment for CV risk factors and systemic/biologic PSO therapy (β=0.31, p=0.03). However, this same relationship was not significant for SAT (β= -0.09, p=0.50). Conclusions: Directly quantified visceral adiposity, but not subcutaneous adiposity, is associated with total HRP score in PSO. These findings suggest that VAT may capture early metabolic risk for HRP development and future cardiovascular events in PSO. Larger prospective studies are needed to confirm these findings.

11/12/17, 9(06 PM

Volume 136, Issue Suppl 1 Table of Contents

Previous Article

Jump to Article Info & Metrics

Article Tools Citation Tools Article Alerts Save to my folders Request Permissions

Share this Article Email Share on Social Media

Related Articles http://circ.ahajournals.org/content/136/Suppl_1/A15886

Page 2 of 5


11/12/17, 9(06 PM

No related articles found.

Google Scholar

Cited By... No citing articles found.

CrossRef

Inflammation Subclinical atherosclerosis Obesity Cardiac CT Adipose

Author Disclosures: J.P. Rivers: None. A. Sajja: None. J.H. Chung: None. A.K. Dey: None. J.B. Lerman: None. A. Rana: None. A. Goyal: None. A.D. Belur: None. A.A. Joshi: None. J.A. Rodante: None. M.P. Playford: None. J. Yao: None. V. Sandfort: None. D.A. Bluemke: None. J.M. Gelfand: Consultant/Advisory Board; Modest; Dr. Gelfand served as a consultant for Coherus (DSMB), Dermira, Janssen Biologics, Merck (DSMB), Novartis Corp, Regeneron, Dr Reddy’s labs, Sanofi and Pfizer Inc.. Other; Modest; Dr. Gelfand received research grants from Abbvie, Janssen, Novartis Corp, http://circ.ahajournals.org/content/136/Suppl_1/A15886

Page 3 of 5


11/12/17, 9(06 PM

Regeneron, Sanofi, Celgene, and Pfizer Inc., Dr. Gelfand received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Abbvie., Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.. M.Y. Chen: None. N.N. Mehta: Research Grant; Modest; Abbvie, Janssen, Novartis Corp, Celgene. © 2017 by American Heart Association, Inc.

Previous Article

Back to top

Circulation About Circulation

Email Alerts

Information for:

Instructions for Authors

Open Access Information

Advertisers

Circulation CME

AHA Journals RSS

Subscribers

Statements and Guidelines

AHA Newsroom

Subscriber Help

Meeting Abstracts

Editorial Oﬃce Address: 200 Fifth Avenue, Suite 1020 Waltham, MA 02451 email: [email protected]

Institutions / Librarians

Permissions Journal Policies

National Center 7272 Greenville Ave. Dallas, TX 75231

Institutional Subscriptions FAQ International Users

ABOUT US

OUR SITES

TAKE ACTION

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More

American Heart Association

Advocate

Customer Service

http://circ.ahajournals.org/content/136/Suppl_1/A15886

American Stroke Association For Professionals More Sites

Donate Planned Giving Volunteer

ONLINE COMMUNITIES AFib Support Garden Community Patient Support Network Professional Online Network

Page 4 of 5


1-800-AHA-USA-1 1-800-242-8721 Local Info Contact Us

11/12/17, 9(06 PM

Careers SHOP Latest Heart and Stroke News AHA/ASA Media Newsroom

Follow Us:

Privacy Policy Copyright Ethics Policy Conflict of Interest Policy Linking Policy Diversity Careers ©2017 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization. *Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

http://circ.ahajournals.org/content/136/Suppl_1/A15886

Page 5 of 5